Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Pharmacoeconomics|November 28, 2017
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert Wolff, Anoukh van Giessen, et al.
BMJ (Clinical Research Ed.)|March 10, 2011
Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trialJudith M Watson, Arthur R Kang'ombe, Marta O Soares, et al.
Complementary Therapies in Clinical Practice|March 30, 2010
A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocolHelen Cox, Helen Tilbrook, John Aplin, et al.
Pharmacoeconomics|October 27, 2022
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|June 10, 2020
Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Nigel Armstrong, Bram Ramaekers, et al.
BMJ (Clinical Research Ed.)|March 24, 2009
Larval therapy for leg ulcers (VenUS II): randomised controlled trialJo C Dumville, Gill Worthy, J Martin Bland, et al.
Pharmacoeconomics|November 15, 2018
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Rob Riemsma, Sabine Grimm, et al.
Pharmacoeconomics|December 15, 2018
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology AppraisalFrederick W Thielen, Nasuh C Büyükkaramikli, Rob Riemsma, et al.
Current Medical Research and Opinion|August 31, 2019
Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalinTitas Buksnys, Nigel Armstrong, Gill Worthy, et al.
Pharmacoeconomics|December 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Antoinette D I van Asselt, Robert Wolff, et al.
Pageof 4